Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 1;33(7):682-5.
doi: 10.1200/JCO.2014.58.9325. Epub 2015 Jan 12.

Expanded RAS: refining the patient population

Chloe E Atreya  1 , Ryan B Corcoran  2 , Scott Kopetz  3
Affiliations

Expanded RAS: refining the patient population

Chloe E Atreya et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Figures

Fig 1.
Fig 1.
Advances in RAS testing. Optimal clinical implementation of RAS testing involves expansion of number of tested codons to include less common mutations and use of assays with sufficient sensitivity for RAS-mutant alleles. To date, preponderance of clinical data reported on expanded RAS mutations has used 5% threshold for detection of mutated (MT)/wild-type (WT) alleles; therefore, this represents a reasonable threshold while additional analyses are conducted.
See this image and copyright information in PMC

References

    1. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–1417. - PubMed
    1. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol. 2010;28:4697–4705. - PubMed
    1. Karapetis CS, Jonker D, Daneshmand M, et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer: Results from NCIC CTG/AGITG CO.17. Clin Cancer Res. 2014;20:744–753. - PubMed
    1. De Roock W, Jonker DJ, Di Nicolantonio F, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010;304:1812–1820. - PubMed
    1. Tejpar S, Celik I, Schlichting M, et al. Association of KRAS G13D tumor mutations with outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol. 2012;30:3570–3577. - PubMed

Publication types

MeSH terms

Substances